Navigation Links
AMT Provides Business Update for the Third Quarter 2009
Date:11/18/2009

s with complete and partial lipoprotein lipase deficiency (LPLD).

On October 8, 2009 AMT received Orphan Drug Designation for its treatment for Duchenne Muscular Dystrophy (DMD).

Prospects

The Company remains on track to file for regulatory approval of its lead product Glybera(R) within the next three months. This gene therapy is to control LPLD, a serious disease often complicated by potentially life threatening pancreatitis incidents.

AMT will continue to develop its own technology platform and exploit its advantages in AAV gene therapy by focusing its preclinical development on 4 projects: Hemophilia B, Duchenne Muscular Dystrophy (DMD), Acute Intermittent Porphyria (AIP) and Parkinson's Disease. Other projects previously shown in the Company's pipeline will be postponed or discontinued to control the Company's cash burn.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases, especially diseases that are caused by one faulty gene. Currently, AMT has a pipeline with several AAV-based gene therapy products at different stages of research or development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "go
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
2. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
3. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
4. Microbix Biosystems Provides a Corporate Update
5. Alexandria Real Estate Equities, Inc. Provides Update
6. SemBioSys provides an update on Botaneco
7. MacuSight(R) Provides Clinical Development Update for Perceiva(TM)
8. New nanostructure technology provides advances in eyeglass, solar energy performance
9. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
10. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
11. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... company that provides innovative genetic analysis solutions, and ... esoteric laboratory services in the United States ... prenatal testing patents and applications. "We have ... and patient care, and we welcome the opportunity to ...
(Date:7/29/2014)... separated from its properties? On July 29, the prestigious ... the first Cheshire Cat experiment, separating a neutron from ... CA, and Vienna University of Technology. , Chesire Cat"Well! ... Alice in Wonderland, "but a grin without a cat! ... my life!" Alice,s surprise stems from her experience that ...
(Date:7/29/2014)... created a new way of manufacturing microstructured surfaces ... by self-assembly of carbon nanotubes, could exhibit a ... stiffness and strength, or the ability to repel ... demonstrated that mechanical forces can be used to ... that we can independently control the mechanical ...
(Date:7/29/2014)... 2014  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: IPXL).  Such investors are advised to contact ... or 888-476-6529, ext. 237. The investigation concerns ... have violated Sections 10(b) and 20(a) of the Securities ... 29, 2014, Impax Laboratories, Inc. (the "Company") issued a ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... 30 VEGA PROMOTIONAL SYSTEMS, INC. (Pink Sheets: VGPR) today ... Power Company, Inc. to assist the Company in building a ... Vega recently announced its intention to build a biomass plant ... materials in the State,s Bioenergy Corridor. Georgia ranks third ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of ... create a comprehensive influenza vaccine solution for the Spanish ... led by the Spanish Ministry of Health and other ...
... Bion Environmental Technologies, Inc. (OTC Bulletin Board: BNET) ... Patent application 11/592,513 entitled "Low Oxygen Biologically Mediated Nutrient ... on November 6, 2006; upon publication and issuance, the ... force until November 5, 2024. This new patent strengthens ...
Cached Biology Technology:Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 3Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 4Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 5Bion Announces Approval of New U.S. Patent that Broadens Protection for the Company's Livestock Waste Environmental Treatment Processes 2
(Date:7/29/2014)... wrong food at a restaurant, don,t blame yourself; blame the ... with what you want and more to do with a ... the selections of over 300 diners, the Cornell study published ... showed that when it comes to what you order ... the menu and how you imagine it will taste. , ...
(Date:7/29/2014)... debilitating effects of a stroke is an immensely ... as well as effective therapy. Advancing such knowledge ... the primary focus of research by Sergei Adamovich, ... the NJIT faculty more than a decade ago. ... substantial funding from sources such as the National ...
(Date:7/29/2014)... developed an easier method to create DNAprotein conjugates. ... in diagnosing diseases. , DNA linked to proteins ... that can be used in diagnostic techniques, nanotechnology ... proteins with DNA can be used for ... of biological material. The method also provides easier ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
... February 20, 2012A team of researchers has found a ... will continue to be available, despite the potential attack ... Disease and poses a significant threat to the California ... Alamos National Laboratory (LANL), University of California at Davis ...
... PA, February 21, 2012 Using a noninvasive test on ... new algorithm for analysis, scientists can detect, with a high ... chromosomal abnormalities that cause Down syndrome and a genetic disorder ... scalable than other recently developed genetic screening tests and has ...
... has awarded The University of Texas at Austin and ... Dynamics Collaboratory (DDC), a network of researchers working to ... reliably predict the physical and ecological evolution of river ... the project, including Paola Passalacqua, assistant professor in Civil, ...
Cached Biology News:More grapes, less wrath: Hybrid antimicrobial protein protects grapevines from pathogen 2Noninvasive method accurately and efficiently detects risk of Down syndrome 2Noninvasive method accurately and efficiently detects risk of Down syndrome 3Engineering, geoscience faculty help lead $3 million NSF Delta research collaboration 2
... The HEEBO (Human Exonic Evidence Based ... Evidence Based Oligonucleotide ) Genome Set contain ... largely derived from constitutively expressed exons, allowing ... collaboration with leading researchers at Stanford University ...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Biology Products: